应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BK1161 生物科技
未开盘 03-05 16:00:00
5,283.230
+148.344
+2.89%
最高
5,390.457
最低
5,135.397
成交量
1.93亿
今开
5,135.397
昨收
5,134.886
日振幅
4.97%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
64.40亿
换手率
--
流通股本
0.00
市净率
6.812936
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
两会｜全国政协委员孙洁：打通创新药落地“最后一公里”
券商中国 · 03-05 23:08
两会｜全国政协委员孙洁：打通创新药落地“最后一公里”
再鼎医药(09688)授出购股权及受限制股份单位
智通财经 · 03-05 22:54
再鼎医药(09688)授出购股权及受限制股份单位
再鼎医药(09688)：Moulder已调任董事
智通财经 · 03-05 22:39
再鼎医药(09688)：Moulder已调任董事
全国政协委员丁列明：建议加强医保基金供给
21世纪经济报道 · 03-05 20:58
全国政协委员丁列明：建议加强医保基金供给
九源基因(02566.HK)公众持股量约为22.22%
中金财经 · 03-05 20:07
九源基因(02566.HK)公众持股量约为22.22%
投资1.54亿，年产18000吨三氟甲苯系列、22000吨苯胺系列等项目批复
市场资讯 · 03-05 19:25
投资1.54亿，年产18000吨三氟甲苯系列、22000吨苯胺系列等项目批复
摩根大通增持信达生物(01801)约40.86万股 每股作价约84.94港元
智通财经 · 03-05 18:58
摩根大通增持信达生物(01801)约40.86万股 每股作价约84.94港元
长江生命科技(00775.HK)拟3月17日举行董事会会议审批年度业绩
中金财经 · 03-05 18:27
长江生命科技(00775.HK)拟3月17日举行董事会会议审批年度业绩
全球尚无同类产品：复宏汉霖HLX97临床试验获批 靶向晚期/转移性实体瘤
财中社 · 03-05 18:01
全球尚无同类产品：复宏汉霖HLX97临床试验获批 靶向晚期/转移性实体瘤
复宏汉霖HLX97（Kat6a/B小分子抑制剂）临床试验申请获国家药监局批准
美股速递 · 03-05 17:32
复宏汉霖HLX97（Kat6a/B小分子抑制剂）临床试验申请获国家药监局批准
君实生物（688180）披露截至2026年2月28日证券变动月报表，3月5日股价上涨0.13%
中金财经 · 03-05 17:24
君实生物（688180）披露截至2026年2月28日证券变动月报表，3月5日股价上涨0.13%
东曜药业-B(01875.HK)拟3月18日举行董事会会议批准年度业绩
中金财经 · 03-05 17:07
东曜药业-B(01875.HK)拟3月18日举行董事会会议批准年度业绩
康希诺生物(06185)获得PIC/S GMP认证
智通财经 · 03-05 16:57
康希诺生物(06185)获得PIC/S GMP认证
MIRXES-B（02629）成功中标2026年濂溪区胃癌筛查与早诊早治项目
美股速递 · 03-05 16:37
MIRXES-B（02629）成功中标2026年濂溪区胃癌筛查与早诊早治项目
MIRXES-B(02629)中标2026年濂溪区胃癌筛查和早期干预项目
智通财经 · 03-05 16:34
MIRXES-B(02629)中标2026年濂溪区胃癌筛查和早期干预项目
每日卖空追踪 | 荣昌生物 03月05日卖空量成交9.85万股，卖空比例为2.5%
市场透视 · 03-05 16:30
每日卖空追踪 | 荣昌生物 03月05日卖空量成交9.85万股，卖空比例为2.5%
每日卖空追踪 | 映恩生物-B 03月05日卖空量成交3.97万股，卖空比例为4.56%
市场透视 · 03-05 16:30
每日卖空追踪 | 映恩生物-B 03月05日卖空量成交3.97万股，卖空比例为4.56%
每日卖空追踪 | 再鼎医药 03月05日卖空量成交58.25万股，卖空比例为4.68%
市场透视 · 03-05 16:30
每日卖空追踪 | 再鼎医药 03月05日卖空量成交58.25万股，卖空比例为4.68%
每日卖空追踪 | 亿腾嘉和 03月05日卖空量成交3.2万股，卖空比例为8.59%
市场透视 · 03-05 16:30
每日卖空追踪 | 亿腾嘉和 03月05日卖空量成交3.2万股，卖空比例为8.59%
每日卖空追踪 | 博安生物 03月05日卖空量成交3.14万股，卖空比例为0.96%
市场透视 · 03-05 16:30
每日卖空追踪 | 博安生物 03月05日卖空量成交3.14万股，卖空比例为0.96%
加载更多
公司概况
公司名称：
BK1161
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5283.2295,"timestamp":1772698103435,"preClose":5134.8857,"halted":0,"volume":192845488,"delay":0,"changeRate":0.028889,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":148.34375,"latestTime":"03-05 16:00:00","open":5135.3965,"high":5390.4565,"low":5135.3965,"amount":6440138239,"amplitude":0.049672,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1772674200000,1772683200000],[1772686800000,1772697600000]],"pbRate":6.812936,"peRate":-87.440914,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2617012578","title":"两会｜全国政协委员孙洁：打通创新药落地“最后一公里”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617012578","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617012578?lang=zh_cn&edition=full","pubTime":"2026-03-05 23:08","pubTimestamp":1772723280,"startTime":"0","endTime":"0","summary":"两会｜全国政协委员孙洁：打通创新药落地“最后一公里”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652257291&idx=4&sn=cd4aec51d92f7b51dca96047551ae824&chksm=851599647b4a496c14a9953197bd97c47fe219fa56f76722b78691eeb3e7afd5890b66eba35d&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159992","BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2617526522","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617526522","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617526522?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:54","pubTimestamp":1772722453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划向4名承授人授出可认购合共8万股美国存托股份的购股权并向9名承授人授出涉及合共12.344万股美国存托股份的受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4526","BK4588","LU2488822045.USD","BK1574","ZLAB","BK4548","BK4531","09688","BK1588","BK4139","BK4585","BK1161"],"gpt_icon":0},{"id":"2617752571","title":"再鼎医药(09688)：Moulder已调任董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2617752571","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617752571?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:39","pubTimestamp":1772721583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，Leon O. Moulder, Jr.先生已调任公司董事，自本公告之日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4526","BK4139","BK4548","ZLAB","BK1574","BK1588","BK1161","LU2488822045.USD","BK4588","BK4585","09688","BK4531"],"gpt_icon":0},{"id":"2617408595","title":"全国政协委员丁列明：建议加强医保基金供给","url":"https://stock-news.laohu8.com/highlight/detail?id=2617408595","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617408595?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:58","pubTimestamp":1772715480,"startTime":"0","endTime":"0","summary":" “过去一年，我参与海南、上海、江苏等多地的生物医药产业专题调研，走访了高校、科研院所和相关企业，深入了解生物医药产业发展的共性问题和挑战”，全国政协委员、贝达药业董事长丁列明近日接受南方财经全国两会报道组采访表示。 对此，丁列明建议，进一步加强医保基金对创新产品的战略购买。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-05/doc-inhpyccf9646094.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-05/doc-inhpyccf9646094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK4585","LABU","BK1574","BK4588"],"gpt_icon":0},{"id":"2617854431","title":"九源基因(02566.HK)公众持股量约为22.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617854431","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617854431?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:07","pubTimestamp":1772712421,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨九源基因(02566.HK)公告，于本公告日期，公司的公众持股量约为22.22%，已低于上市规则第19A.28B条所规定公众股东持有公司已发行股份总数的25.0%(\"最低规定百分比\")。\r\n\r\n 公司公众持股量的不足，乃由于近期根据公司股东于2025年6月11日举行的股东周年大会上授予董事会的购回授权，回购公司H股所致，使得其中一名公众股东转变成为上市规则所定义的主要股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"2617549534","title":"投资1.54亿，年产18000吨三氟甲苯系列、22000吨苯胺系列等项目批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549534","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617549534?lang=zh_cn&edition=full","pubTime":"2026-03-05 19:25","pubTimestamp":1772709900,"startTime":"0","endTime":"0","summary":"近日，关于关于内蒙古大中实业化工有限公司年产18000吨三氟甲苯系列、22000吨苯胺系列、1000吨五氟磺草胺、1000吨炔草酯、1000吨吡氟酰草胺项目批复公示。项目总投资15400.0万元，其中环保投资1000.0万元，占总投资的6.49%产品方案5-氯-2-氨基三氟甲苯外观为无色液体，主要用于染料、农药、医药中间体，本项目中主要作为农药中间体使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-05/doc-inhpxwvh3123827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2617278545","title":"摩根大通增持信达生物(01801)约40.86万股 每股作价约84.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617278545","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617278545?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:58","pubTimestamp":1772708286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，2月27日，摩根大通增持信达生物(01801)40.863万股，每股作价84.9352港元，总金额约为3470.71万港元。增持后最新持股数目约为8690.81万股，最新持股比例为5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1084165304.USD","BK4581","LU0211331839.USD","LU1032466523.USD","IE00B1BXHZ80.USD","LU2505996509.AUD","LU0964807845.USD","BK1161","BK1589","IE00BKDWB100.SGD","LU1974910355.USD","LU2023250504.SGD","LU1668664300.SGD","LU1551013425.SGD","LU0787776722.HKD","LU0640476718.USD","LU1145028129.USD","LU0496365809.HKD","IE00BJLML261.HKD","LU2097828714.EUR","JPMO","LU1116320901.HKD","LU1366192091.USD","LU0345770308.USD","BK1583","LU2430703251.USD","LU2462157665.USD","LU0882574139.USD","LU1988902786.USD","LU2552382058.USD","LU0170899867.USD","LU2242644610.SGD","LU0971096721.USD","LU1894683264.USD","LU0203345920.USD","LU2430703095.HKD","LU2746668461.USD","HK0000165453.HKD","LU2106854487.HKD","LU2456880835.USD","01801","IE00B1XK9C88.USD","IE00BZ1G4Q59.USD","LU2237443549.SGD","LU2237443895.HKD","LU0208291251.USD","LU1969619763.USD","LU0149725797.USD","LU0868494708.USD","LU1720051017.SGD"],"gpt_icon":0},{"id":"2617454314","title":"长江生命科技(00775.HK)拟3月17日举行董事会会议审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2617454314","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617454314?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:27","pubTimestamp":1772706424,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨长江生命科技(00775.HK)宣布，公司将于2026年3月17日(星期二)于香港举行董事会会议，以(其中包括)批准刊发公司及其附属公司截至2025年12月31日止财政年度之业绩，以及考虑派发末期股息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["00775","BK1161","BK1569"],"gpt_icon":0},{"id":"2617254829","title":"全球尚无同类产品：复宏汉霖HLX97临床试验获批 靶向晚期/转移性实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254829","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617254829?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:01","pubTimestamp":1772704905,"startTime":"0","endTime":"0","summary":"3月5日，复宏汉霖（02696）发布公告，公司自主研发的HLX97（KAT6A/B小分子抑制剂）在晚期/转移性实体瘤患者中的1期临床试验申请获得国家药品监督管理局批准。HLX97旨在治疗晚期/转移性实体瘤，具有良好的抗肿瘤效果和安全性特征。截至公告日，全球范围内尚无KAT6A/B小分子抑制剂获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053663266538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","HK0000320223.HKD","HK0000320264.USD","HK0000165453.HKD","HK0000306685.HKD","HK0000306701.USD","02696"],"gpt_icon":0},{"id":"1171280574","title":"复宏汉霖HLX97（Kat6a/B小分子抑制剂）临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1171280574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171280574?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:32","pubTimestamp":1772703177,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其自主研发的HLX97（一种针对Kat6a/B的小分子抑制剂）临床试验申请，已获得国家药品监督管理局（NMPA）的正式批准。\n此次获批标志着该创新药物将进入临床开发阶段，为公司肿瘤治疗领域的管线增添了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000320264.USD","HK0000320223.HKD","02696","HK0000306685.HKD","BK1161","HK0000306701.USD"],"gpt_icon":0},{"id":"2617517006","title":"君实生物（688180）披露截至2026年2月28日证券变动月报表，3月5日股价上涨0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517006","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517006?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:24","pubTimestamp":1772702658,"startTime":"0","endTime":"0","summary":"公司于近日披露《截至2026年2月28日的证券变动月报表》。公告显示，截至2026年2月28日，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于香港联交所上市，A股于上交所科创板上市。股份期权计划方面，H股及A股股票期权激励计划已于2025年9月29日获批准采纳，本月无新增行权或股份变动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260305/32047274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688180","BK1515","161027","BK1161","BK0239","BK1583","01877"],"gpt_icon":0},{"id":"2617512147","title":"东曜药业-B(01875.HK)拟3月18日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2617512147","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617512147?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:07","pubTimestamp":1772701629,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨东曜药业-B(01875.HK)宣布，公司谨定于2026年3月18日(星期三)举行董事会会议，以考虑及通过本集团截至2025年12月31日止年度的全年业绩，以及处理其他事项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","01875"],"gpt_icon":0},{"id":"2617917512","title":"康希诺生物(06185)获得PIC/S GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617917512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617917512?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:57","pubTimestamp":1772701020,"startTime":"0","endTime":"0","summary":"PIC/S为国际药品检查、认证的权威机构，由数十个国家的药品监管机构组成，以统一标准对人用和兽用药品的GMP实施检查、认证，GMP符合性检查是药品注册上市的必要条件之一。在自愿的基础上，PIC/S成员国及参与机构之间执行 GMP符合性检查互认。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","BK1515","BK1574","06185"],"gpt_icon":0},{"id":"1105145978","title":"MIRXES-B（02629）成功中标2026年濂溪区胃癌筛查与早诊早治项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1105145978","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105145978?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:37","pubTimestamp":1772699830,"startTime":"0","endTime":"0","summary":"MIRXES-B（02629）近日宣布，公司已成功中标2026年濂溪区胃癌筛查与早期干预项目。这一重要成果标志着公司在癌症早筛领域的专业能力与市场竞争力获得权威认可，为其未来业务拓展奠定了坚实基础。\n该项目旨在通过先进的筛查技术，实现胃癌的早期发现与及时干预，从而有效提升区域居民健康水平。MIRXES-B凭借其创新的检测方案与丰富的项目经验，在竞标中脱颖而出，展现了企业在精准医疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02629","BK1161"],"gpt_icon":0},{"id":"2617514706","title":"MIRXES-B(02629)中标2026年濂溪区胃癌筛查和早期干预项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2617514706","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617514706?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:34","pubTimestamp":1772699688,"startTime":"0","endTime":"0","summary":"智通财经APP讯，MIRXES-B 发布公告，于2026年3月3日，公司成功中标2026年濂溪区胃癌筛查和早期干预项目，这是公司首个公共卫生癌症早筛项目，也是其在中国首个政府采购项目，标志着其miRNA液体活检技术正式进入公共卫生体系，为胃癌早筛规模化落地奠定关键基础。该项目预算金额人民币810.0万元，最高投标价人民币769.5万元，将为中国江西九江濂溪区约3万名居民提供胃癌早筛服务。预期该项目将提升当地胃癌早期检出率，加强地区癌症防控架构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"MIRXES-B(02629)中标2026年濂溪区胃癌筛查和早期干预项目","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02629"],"gpt_icon":0},{"id":"2617952321","title":"每日卖空追踪 | 荣昌生物 03月05日卖空量成交9.85万股，卖空比例为2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617952321","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617952321?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699443,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间03月05日，涨7.03%，卖空量成交9.85万股，较上一交易日减少87.26%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163624a6a5dc10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163624a6a5dc10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU1969619763.USD","BK1574","09995","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2617552012","title":"每日卖空追踪 | 映恩生物-B 03月05日卖空量成交3.97万股，卖空比例为4.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617552012","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617552012?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699442,"startTime":"0","endTime":"0","summary":"映恩生物-B北京时间03月05日，涨2.18%，卖空量成交3.97万股，较上一交易日减少74.12%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163604a6a5db84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163604a6a5db84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2543165471.USD","09606","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"2617510670","title":"每日卖空追踪 | 再鼎医药 03月05日卖空量成交58.25万股，卖空比例为4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617510670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617510670?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699442,"startTime":"0","endTime":"0","summary":"再鼎医药北京时间03月05日，涨3.93%，卖空量成交58.25万股，较上一交易日减少74.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163619a6a5dbf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163619a6a5dbf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","LU2488822045.USD","BK1588","09688"],"gpt_icon":0},{"id":"2617576228","title":"每日卖空追踪 | 亿腾嘉和 03月05日卖空量成交3.2万股，卖空比例为8.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617576228?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699439,"startTime":"0","endTime":"0","summary":"亿腾嘉和北京时间03月05日，涨4.78%，卖空量成交3.2万股，较上一交易日减少32.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163600a44efa57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163600a44efa57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06998","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2617523410","title":"每日卖空追踪 | 博安生物 03月05日卖空量成交3.14万股，卖空比例为0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523410","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617523410?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699439,"startTime":"0","endTime":"0","summary":"博安生物北京时间03月05日，涨0.14%，卖空量成交3.14万股，较上一交易日减少75.77%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163603a44efa6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163603a44efa6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06955","BK1161"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0402},{"period":"1month","weight":-0.0564},{"period":"3month","weight":-0.0293},{"period":"6month","weight":-0.0038},{"period":"1year","weight":0.0732},{"period":"ytd","weight":-0.0121}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}